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A B S T R A C T
Purpose
Observational study evidence has associated overweight/obesity with decreased survival in women
with breast cancer and with several other cancers. Although full-scale, deﬁnitive weight loss ad-
juvant intervention trials with cancer end points remain to be conducted, a number of randomized
controlled trials have evaluated weight loss interventions in survivors of cancer in women. Findings
from these trials in breast, endometrial, and ovarian cancer are reviewed.
Methods
A systematic review of randomized controlled clinical trials evaluating weight loss interventions was
updated (for studies published 2013 to 2016), and clinical trials registers were searched for ongoing
trials.
Results
Six new randomized trials in breast cancer survivors and two randomized trials in endometrial cancer
survivors were identiﬁed. Evidence from these trials and the 10 earlier randomized trials in female
cancer survivors provide support for the feasibility of recruiting women closer to the cancer di-
agnosis and efﬁcacy for achieving weight loss, in particular with telephone-based interventions, and
have identiﬁed the challenge of achieving signiﬁcant weight loss in African American cancer sur-
vivors and of maintaining weight loss in any cancer survivor group. Seven ongoing randomized trials
are evaluating the inﬂuence of weight loss interventions on cancer end points (ﬁve in breast cancer,
one in ovarian cancer, and one in endometrial cancer).
Conclusion
After a decade of preliminary studies, ongoing randomized, controlled clinical trials will potentially
provide deﬁnitive assessment of whether weight loss can improve breast cancer clinical outcome.
Longer-term interventions (. 2 years’ duration)may be needed to optimizeweight lossmaintenance
and any potential beneﬁts on cancer end points.
J Clin Oncol 34:4238-4248. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Obesity has been associated with adverse survival
outcome in women with early-stage breast can-
cer in a series of observational studies1-3 begin-
ning . 40 years ago, with a considerable body of
supportive evidence available by 2002.4 In 2006,
ﬁndings from the randomized Women’s In-
tervention Nutrition Study provided support for
a potential inﬂuence of weight control on breast
cancer outcome.5 In this trial, which enrolled
2,437 postmenopausal women with early-stage
breast cancer, fat intake and body weight de-
creased in the dietary group, and a signiﬁcant
improvement in relapse-free survival was seen.5
In 2009, a National Cancer Institute–sponsored
conference outlined the clinical trial rationale for
studies of weight control and breast cancer out-
come.6 The most recent meta-analysis of obser-
vational studies reported an increased risk of total
mortality of 20% to 40% and breast cancer
mortality of 25% to 35% in obese breast cancer
survivors compared with their healthy-weight
counterparts (on the basis of weight prediag-
nosis and within 12 months postdiagnosis).1
Against this background of decades of accumu-
lating information regarding the association be-
tween obesity and breast cancer adverse outcome,
deﬁnitive trial evidence from weight loss in-
tervention trials in breast cancer survivors re-
mains lacking. Finally, in 2015 recommendations
for obesity clinical trials in cancer survivors were
put forward in an ASCO Statement.7
Rowan T. Chlebowski, Harbor–University
of California, Los AngelesMedical Center,
Torrance, CA; and Marina M. Reeves,
The University of Queensland, Brisbane,
Queensland, Australia
Published online ahead of print at
www.jco.org on November 7, 2016.
The Women’s Health Initiative program is
supported by the National Heart, Lung,
and Blood Institute through contracts No.
N01WH22110, 24152, 32100-2, 32105-6,
32108-9, 32111-13, 32115, 32118-32119,
32122, 42107-26, 42129-32, and 44221;
and by American Institute for Cancer
Research Grant No. 30210-01 (R.T.C.).
M.M.R. is supported by a fellowship from
the Australian National Breast Cancer
Foundation.
Authors’ disclosures of potential conﬂicts
of interest are found in the article online at
www.jco.org. Author contributions are
found at the end of this article.
Corresponding author: Rowan T.
Chlebowski, MD, PhD, Los Angeles
Biomedical Research Institute at
Harbor–University of California, Los
Angeles Medical Center, 1124 W Carson
St, Torrance, CA 90502; e-mail:
rowanchlebowski@gmail.com.
© 2016 by American Society of Clinical
Oncology
0732-183X/16/3435w-4238w/$20.00
DOI: 10.1200/JCO.2016.69.4026
4238 © 2016 by American Society of Clinical Oncology
VOLUME 34 • NUMBER 35 • DECEMBER 10, 2016
Downloaded from ascopubs.org by University of Queensland on January 22, 2017 from 130.102.082.101
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
In 2014, Reeves and colleagues8 published a systematic review
of weight loss intervention trials in women with breast cancer
including studies reported up until June 2013. Ten randomized
controlled trials evaluating behaviorally based weight loss in-
terventions inwomenwith breast cancer were identiﬁed9-18 and are
summarized here. These trials recruited relatively small samples,
ranging from 2411,16 to 1029 women with early-stage breast cancer.
One study was limited to a subgroup of breast cancer survivors,
broadly deﬁned as those with estrogen receptor (ER) –positive
tumors,18 and two exclusively recruited African American or
Hispanic women.11,12 Five studies reported mean time since di-
agnosis at baseline, with this ranging from 3.5 to 5.6 years.10-12,14,18
Interventions varied considerably in their behavioral targets,
delivery, and duration. Six trials targeted both diet and physical
activity,10-15 with the remaining four addressing dietary intake
only. Most interventions were delivered by face-to-face sessions;
however, three included intervention arms delivered primarily
via telephone,10,11,13 and one included combined telephone and
face-to-face sessions.14 Six studies evaluated interventions
of # 6 months’ duration,12,14-18 and the remaining four studies
evaluated interventions of $ 12 months.9-11,13 Weight loss was
the primary outcome reported in all studies. Statistically signiﬁcant
weight loss was observed inmost intervention arms, with six studies
achieving clinically meaningful mean weight loss of at least 5% of
initial body weight.9,10,13,14,17,18
Various other outcomes were assessed in most of these trials;
however, most were underpowered to detect these. Six measured
clinical biomarkers,10,12-15,18,19 with relatively consistent changes
seen in reductions in LDL cholesterol and glucose in groups losing
weight. Five trials reported on insulin pathways, adipokines, and
inﬂammatory markers, all factors associated with breast cancer
progression.20,21 In two trials, where weight losses of . 5% were
seen, reductions in insulin levels and insulin resistance were
found.10,18,19 C-reactive protein was measured in three trials,12,15,18
with a nonstatistically signiﬁcant reduction of 7% to 9% in the one
trial with mean weight loss . 5%.18
Despite the relatively small sample sizes and heterogeneous
interventions, these trials provided promising evidence that weight
loss is safe and feasible to achieve (although of variable magnitude)
in women diagnosed with breast cancer. However, few studies
aimed to recruit women close to their breast cancer diagnosis.
Furthermore, these studies are limited by their general focus on
short-term weight loss and weight change as the primary outcome.
There is little rationale to suggest that weight loss interventions and
strategies, well-established to be effective in similar age women
without cancer, would differ in their effectiveness in women with
breast cancer or that the impact on metabolic and inﬂammatory
biomarkers would differ. The real need is to determine whether
effective weight loss interventions can be implemented in women
with breast cancer closer to diagnosis, when they could potentially
inﬂuence the higher recurrence risk seen in the ﬁrst years after
a breast cancer diagnosis.22,23
The systematic review by Reeves and colleagues8 identiﬁed
a number of ongoing trials, aimed to address novel research
questions and outcomes in powered trials in breast cancer sur-
vivors. The aim of this systematic review was to update the evi-
dence on weight loss interventions published over the previous
3 years and to identify ongoing trials with cancer end points.
Because obesity has been associated with incidence24-26 and poorer
outcomes27-30 for women diagnosed with other female cancers,
such as ovarian and endometrial cancer, we also sought to re-
view the recent evidence on weight loss interventions in these
populations.
METHODS
Following the Preferred Reporting Items for Systematic Reviews andMeta-
Analyses (PRISMA) guidelines,31 we conducted a structured search of
PubMed (from July 1, 2013) and Web of Science (from January 1, 2013) to
July 14, 2016. Titles and abstracts were searched using the following search
strategy: (intervention OR programOR trial) AND (RCTOR random* OR
control OR arm) AND (cancer AND (breast OR endometri* OR uter* OR
ovar*) AND (weight loss OR weight-loss OR weight management OR
weight control ORweight change). Titles and abstracts and full texts, where
needed, were screened independently by M.M.R. and a research assistant,
with any disagreements resolved by discussion. For inclusion, the publi-
cation had to report on results of a randomized trial evaluating a behav-
iorally based weight loss intervention (calorie restriction with or without
exercise/physical activity) in women diagnosed with breast, endometrial,
or ovarian cancer. Data were extracted by the research assistant and in-
dependently reviewed by M.M.R. Risk of bias was also assessed, consistent
with the previous review.8
A search of two clinical trials registers (ClinicalTrials.gov and the
International Standard Randomized Controlled Trial Number Registry,
www.isrctn.com) was also conducted to identify ongoing randomized trials
of weight loss interventions in women with breast, endometrial, or ovarian
cancer. Those reporting on cancer end points were of particular interest,
with those reporting on efﬁcacy or intermediate outcomes also identiﬁed.
RESULTS
The search identiﬁed 311 records, of which 10 publications (from
eight individual studies) were considered eligible (Fig 1).32-41 Six
were conducted in breast cancer survivors and two in endometrial
cancer survivors (Table 1). Risk of bias was considered high in two
studies,37,38 moderate in four,32,34,40,41 and low in two33,39 (Ap-
pendix Table A1, online only).
Completed Randomized Controlled Trials
Breast cancer. Among the six trials, sample size ranged from
2237 to 692,34 with two larger-scale trials.33,34 All trials included
women with early-stage invasive breast cancer, with two also in-
cluding stage 0 disease.32,39 One trial recruited women with ER-
positive tumors treated with letrozole,33 one trial recruited only
women with triple-negative breast cancer,38 and one trial exclu-
sively recruited African American women.37 Women were
recruited on average 9.4 months33 up to 4 to 5 years post-
diagnosis.37 All of the trials evaluated interventions targeting diet and
exercise; however, the method of delivery and duration differed
considerably.
The two larger-scale trials are discussed in detail, with the
remaining trials summarized brieﬂy ﬁrst. The Daughters and
Mothers Against Breast Cancer (DAMES) trial aimed to recruit
a unique population, namely mother-daughter dyads.32 The in-
tervention was delivered via mailed materials over 12 months.
Dyads were randomly assigned to receive individually tailored
www.jco.org © 2016 by American Society of Clinical Oncology 4239
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materials, team-tailored materials, or standardized materials
(control). Compared with control (20.9 kg), 12-month weight
change was signiﬁcantly greater in survivors in the individually
tailored group (23.8 kg) but not statistically different in the team-
tailored group (22.1 kg). Although the overall retention rate in this
trial was high (90%), recruitment of mother-daughter dyads
proved difﬁcult.
The Stepping STONE (Survivors Taking on Nutrition and
Exercise) study randomly assigned 31 African American women
diagnosed with stage I to III breast cancer on average 1.7 years
before to a 12-week, culturally tailored intervention or usual care.37
The intervention included alternating once-weekly group sessions
(delivered by nutritionist and exercise physiologist) and individual
telephone counseling sessions (peer-delivered by trained survi-
vors). Change in weight in the intervention group was minimal,
with no signiﬁcant difference between groups, highlighting the
previously identiﬁed challenge of achieving clinically meaningful
weight loss in this population.11,12,42
Swisher and colleagues38 randomly assigned 28 women with
triple-negative breast cancer (ER/progesterone receptor/human
epidermal growth factor receptor 2 [HER2] –negative), on average
4 to 5 years postdiagnosis, to a 12-week intervention or control. The
intervention included an exercise component involving three su-
pervised exercise sessions plus two unsupervised sessions per week. In
comparison, the dietary component of the intervention included only
two face-to-face sessions with a dietician (a month apart), with the
focus primarily on decreasing caloric intake from fat by 200 kcal/day.
No statistically signiﬁcant difference in weight was observed, al-
though sample size was small (23.0 kg v20.4 kg). Importantly, the
intervention group observed statistically signiﬁcant and clinically
meaningful improvements in quality of life.
The Lifestyle Exercise and Nutrition (LEAN) study randomly
assigned 100 women with stage 0 to III breast cancer (on aver-
age 2.9 years postdiagnosis) to one of three study arms: face-to-
face counseling, telephone counseling, or control.39 The two in-
tervention arms received the same lifestyle intervention (500 kcal/day
energy deﬁcit, , 25% energy from fat, predominantly plant-based
diet, 150minutes per week of moderate-intensity activity) and same
number of contacts (11 sessions tapered over 6 months) but dif-
fered in the method of delivery. Intervention adherence was slightly
higher in the face-to-face counseling group (88% v 71% attend-
ing at least 80% of sessions), although no statistically signiﬁcant
Duplicates excluded across databases (n = 49)
Publications included (from eight
  trials; n = 10)
Trials in breast cancer
survivors                          
Trials in endometrial 
  cancer survivors              
Publications screened (n = 262)
Records
identified through
database searching (N = 311)
Full-text publications screened (n = 33)
Publications excluded based on full text review             (n = 23)
Not a randomized trial
Not a behaviorally based weight loss intervention
Protocol or recruitment paper only
Included in previous review
(n = 9)
(n = 3)
(n = 7)
(n = 4)
Not human (n = 13)
(n = 147)
(n = 14)
(n = 48)
(n = 7)
Publications excluded based on title/abstract review   (n = 229)
Not reporting results from an intervention trial
  (original research)    
Not in women diagnosed with breast, endometrial,
or ovarian cancer
Not a behaviorally based weight loss intervention
Results presented in abstract form only
(n = 6)
(n = 2)
Fig 1. Preferred reporting items for systematic reviews
and meta-analyses ﬂow of literature search.
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difference in weight loss at 6 months was observed between the two
intervention groups (26.4% v 25.4%, P = .46), and both were
signiﬁcantly greater than usual care (21.7%).
Lifestyle Intervention Study in Adjuvant Treatment of Early
Breast Cancer trial. The Lifestyle Intervention Study in Adjuvant
Treatment of Early Breast Cancer (LISA) trial33 was a multicenter,
randomized controlled trial evaluating a telephone-delivered
lifestyle intervention versus brief, mail-based intervention,
with participants recruited from 16 Canadian and four US
centers. The trial aimed to examine whether the weight loss
intervention could favorably inﬂuence clinical outcome (ie,
disease-free survival) in overweight and obese postmenopausal
women with early-stage breast cancer as an addition to con-
ventional cancer management. However, the trial was terminated
after 338 randomizations (of a planned 2,150) when funding was
lost. Eligible participants were postmenopausal women with
early-stage, ER-positive breast cancer (body mass index [BMI], 24
to 40 kg/m2) receiving letrozole. At study entry, participants were
on average 9.4 months postdiagnosis, with a mean age of 61 years
and mean BMI of 31 kg/m2.
The lifestyle intervention was delivered over 2 years, with up
to 19 telephone calls on a tapered schedule. The intervention was
designed to achieve 10%weight loss through a reduction in calories
(500 to 1,000 kcal/day deﬁcit) and fat (20% of calories); increased
intakes of fruits, vegetables, and grains; and increasing to 150 to
200 minutes per week of moderate-intensity aerobic physical
activity (primarily walking). Overall, 81.1% of scheduled calls
were completed by intervention participants, with 62% com-
pleting all 19 calls. Study retention at 24-month follow-up was
78.1%.
Mean weight loss was signiﬁcantly (P , .001) greater in the
lifestyle intervention group than themail-based intervention group
at all follow-up time points (25.5% v20.7% at 12months;23.6%
v 20.4% at 24 months), although a slight regain in weight was
observed at 24 months. Physical activity levels were signiﬁcantly
greater in the lifestyle intervention versus mail-based intervention
over the 24-month follow-up, although changes in dietary intake
were less consistently observed. Despite early termination of re-
cruitment, participants continue to be followed postintervention
for clinical outcomes.
Exercise and Nutrition to Enhance Recovery and Good
Health to You trial. The Exercise and Nutrition to Enhance
Recovery and Good Health to You (ENERGY) trial34 was designed
as a vanguard trial to inform a full-scale, deﬁnitive trial powered for
cancer end points. The vanguard trial aimed to establish effec-
tiveness of the intervention for achieving and maintaining weight
loss and improvements in quality of life in overweight/obese breast
cancer survivors. Women with stage I to III breast cancer and BMI
of 25 to 45 kg/m2 were recruited from four US sites on average
2 years post primary treatment completion and randomly assigned
to weight loss intervention or control groups. The intervention
was delivered primarily by face-to-face group sessions (26 ses-
sions over 12 months on tapered frequency), with telephone calls
or emails (24 to 38 in total over 2 years) and tailored newsletters
(quarterly from 6 to 24 months), designed to achieve 7% weight
loss through reduction in calories (500 to 1,000 kcal/day deﬁcit)
and increasing physical activity (60 minutes per day moderate-
intensity planned exercise and two to three sessions per week
resistance exercise).43 Study retention at 24 months was 84.8%.
Intervention adherence was not reported.
Signiﬁcantly greater weight loss was seen in the intervention
group compared with controls at 12 and 24 months (26.0%
v 21.5% and 23.7% v 21.3%, respectively), albeit with some
regain in weight observed at 24 months. Importantly, multivariable
analysis showed that, in addition to intervention assignment, age
was the only other predictor of maintained weight loss at
24 months, with no weight loss seen at 24 months in women in the
intervention arm age 30 to 44 years. A signiﬁcant difference in new
medical conditions diagnosed in the intervention group versus the
control group at 12-month follow-up was observed (19.6% v
32.2%, P, .001), but there was no difference at 24-month follow-
up (26.2% v 22.0%, P = .27).36 Furthermore, a beneﬁcial effect of
the intervention versus control on vitality and physical function
(the primary quality-of-life outcomes) was observed only at
6 months, but it diminished over time.35 Of concern were de-
pressive symptoms, which increased in the intervention group and
were statistically signiﬁcantly higher than in the control group at
24 months.35 Because no minimum clinically important difference
has been established for the depressive symptom tool used (Centre
for Epidemiologic Studies Depression Scale), it is difﬁcult to de-
termine if the relatively small effect size observed (approximately
0.2) is clinically meaningful. Further understanding of this ﬁnding
is warranted, with assessment of depressive symptomology an
important outcome for future trials.
A limitation of the ENERGY trial is the large reliance on face-
to-face intervention delivery over the ﬁrst year. Face-to-face
contacts are costly (both from provider and patient perspective),
thus affecting wider-scale implementation and upscale.
Endometrial cancer. The two trials in endometrial cancer
survivors are summarized in Table 1. The Survivors of Uterine
Cancer Empowered by Exercise and Health Diet (SUCCEED)
trial40 randomly assigned 75 overweight and obese women with
stage I or II endometrial cancer (on average 20.7 months post-
diagnosis) to a 12-month intervention or usual care. The in-
tervention was delivered primarily via group face-to-face sessions
in the ﬁrst 6 months, with support provided via newsletters and
telephone/e-mail in the second 6 months. A signiﬁcant difference
in weight change between groups was observed at 12 months
(23.0% v +1.4%).44 Short-term (3- and 6-month) within- and
between-group improvements in some domains of quality of life
were observed.40
Haggerty and colleagues41 recruited 16 women (BMI .
30 kg/m2) with stage I to III endometrial cancer and four women
with endometrial hyperplasia, who were randomly assigned to
one of two weight loss interventions. The telephone in-
tervention group received up to 20 telephone calls over the
6-month intervention (once weekly for the ﬁrst 16 weeks and then
biweekly) and were provided with a WiFi scale for once-weekly
recording of weight. The text message intervention group re-
ceived between three and ﬁve text messages once daily focused
on intervention messages. Diet and physical activity targets
were the same between the two interventions. Mean weight
change was reported for the 90% of participants who lost
weight, suggesting greater weight loss with the telephone-delivered,
compared with the text message–based, intervention (median,
7.6% v 24.1%).
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Table 1. Recent Randomized Controlled Trials Evaluating Weight Loss Interventions
Study Sample Study Arms/Intervention Characteristics Outcomes
Breast cancer survivors
DAMES32
2014
United States
Risk of bias: 5/10
(moderate)
68 mother-daughter dyads (136
postmenopausal women and their
daughters)
Mothers: stage 0-III breast cancer
Mean 24 months since diagnosis
Mean BMI (mothers), 31.0 kg/m2
Mean age (mothers), 61.3 years
Ethnicity: 74% white
Recruited through Web sites, ﬂyers,
community presentations, Duke cancer
clinic
12-month intervention
(1) Individual: tailored diet and exercise
materials (workbook plus six tailored
newsletters). Participants’ food and PA
logs and bimonthly surveys used to
tailor following newsletters. 150
minutes per week of aerobic exercise,
strength training twice per week
(unsupervised)
(2) Team: tailored diet and exercise
materials identical to those in individual
arm but also received information on
their other team member
(3) Control: bimonthly healthy eating– and
PA-promoting brochures and pamphlets.
Bimonthly surveys assessed the
helpfulness of each brochure.
Change from baseline to 12 months:
Mothers
(1) 23.77 6 4.8 kg
(2) 22.09 6 4.3 kg
(3) 20.87 6 2.97 kg
1 v 3*; 2 v 3
Retention rate 5 90%
LISA33
2014
United States
Risk of bias: 8/10
(low)
338 postmenopausal women
Stage T1-3, N0-2, M0 ER-positive breast
cancer and receiving letrozole
Mean 9.4 months since diagnosis
Mean BMI, 31.3 kg/m2
Mean age, 61.0 years
Ethnicity: 96% white
Multicenter recruitment
24-month intervention
(1) Lifestyle intervention: telephone-
delivered intervention; 19 calls in total
(tapered schedule: weekly, biweekly,
monthly, bimonthly). Goal of 10%
weight loss; calorie reduction of 500-
1,000 kcal/day; fat approximately 20%
of calories; increase intake of fruit,
vegetables, and grains; 150-200
minutes per week of moderate-intensity
aerobic PA (unsupervised)
(2) Mail-based education intervention:
mailed information on healthy diets, PA,
breast cancer, other common medical
issues, and a 2-year subscription to
Canadian Health Magazine
Change from baseline to
12 months:
(1) 25.5 6 6.4%
(2) 20.7 6 6.6%
1 v 2*
24 months:
(1) 23.6 6 7.7%
(2) 20.4 6 6.4%
1 v 2*
Retention rate 5 78%
ENERGY34-36
2015
United States
Risk of bias: 7/10
(moderate)
692 pre- and postmenopausal women
Stage I (. 1 cm), II, III breast cancer
Mean 2.1 years post treatment
completion
Mean BMI, 31.5 kg/m2
Mean age, 56.0 years
Ethnicity: 81% white
Recruited through cancer registries,
clinics, media, community support
groups and events
24-month intervention
(1) Intensive intervention: group-based
sessions (tapered from weekly to
biweekly to monthly in ﬁrst 12 months;
26 group sessions in total); individual
telephone and/or e-mail contacts (total of
24-38 contacts over 2 years); tailored
newsletters provided quarterly from
months 6-24. Goal of 7% weight loss at
2 years; deﬁcit of 500-1,000 kcal/day;
decreasing energy density; and aim 60
minutes per day of moderate-intensity PA
2) Control (less intensive): provided with
general weight management resources
and materials, individualized counseling
at baseline and 6 months, and PA
recommendation of 30 minutes per day.
Participants also received monthly
telephone calls and/or e-mail invitations
to optional seminars on aspects of
healthy living bimonthly in year 1.
Change from baseline to
12 months:
(1) 26.0% (0.4)
(2) 21.5% (0.4)
1 v 2*
24 months:
(3) 23.7% (0.4)
(4) 21.3% (0.4)
1 v 2*
Retention rate 5 85%
In multivariable analysis, study arm and
age were only signiﬁcant predictors of
weight change at 24 months.
Signiﬁcantly fewer new medical
conditions in intervention group v
control at 12 months (19.6% v 32.2%;
P , .001) but not 24 months (26.2% v
22.0%; P 5 .27)
QoL—signiﬁcant difference in physical
function at 6 months but not at 12 or
24 months; no signiﬁcant difference in
vitality at any follow-up
Depressive symptoms signiﬁcantly higher in
intervention group at 24 months (P5 .03)
Stepping STONE37
2015
United States
Risk of bias: 2/10
(high)
31 women (menopausal status NR)
Stage I-III breast cancer
Mean 1.7 years post treatment
completion
Mean BMI, 36.4 kg/m2
Mean age, 54.7 years
Ethnicity: 100% African American
Recruited through two hospitals, ﬂyers at
community events, local newspapers
12-week intervention
(1) Face-to-face group sessions and
telephone counseling: biweekly 90-
minute group sessions including 60-
minute education session (including
cooking demonstrations) delivered by
study nutritionist and 30 minutes PA
supervised by EP. Biweekly telephone
coaching sessions (15minutes) delivered
by trained survivor coach. Goal 5%
weight loss;. 30minutes per day on$ 5
days per week moderate intensity; $ 5
servings fruit and vegetables per day;
, 35% kcal from total fat
(2) Control: provided general health
information for cancer survivors.
Offered the intervention at the end of
the study.
Change from baseline to 12 weeks:
(1) 20.8 kg (SD NR)
(2) 0.2 kg (SD, NR)
1 v 2 (ns)
Retention rate 5 70%
(continued on following page)
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Table 1. Recent Randomized Controlled Trials Evaluating Weight Loss Interventions (continued)
Study Sample Study Arms/Intervention Characteristics Outcomes
Swisher38
2015
United States
Risk of bias: 2/10
(high)
28 women (menopausal status NR)
Stage I-III with conﬁrmed ER/PR/HER2-
negative status
Mean 4-5 years since diagnosis
Mean BMI, 31.5 kg/m2
Mean age, 53.7 years
Ethnicity: NR
Recruited through oncology visits
12-week intervention
(1) Intervention: three supervised
moderate-intensity aerobic exercise
sessions per week with EP and two
unsupervised sessions per week.
Strength training during supervised
sessions was optional. Two individual
dietary counseling sessions 1 month
apart. Goal of decreasing dietary fat by
200 kcal/week.
(2) Control: participants received written
materials about healthy eating for
cancer survivors and suggestions on
ways to achieve regular PA.
Change from baseline to 12 weeks:
(1) 23.0 kg
(2) 20.4 kg
1 v 2 (ns)
Retention rate 5 72%
LEAN39
2016
United States
Risk of bias: 8/10
(low)
100 pre- and postmenopausal women
Stage 0-III breast cancer
Mean 2.9 years since diagnosis
Mean BMI, 33.1 kg/m2
Mean age, 59.0 years
Ethnicity: 91% white
Recruited through ﬁve hospitals
6-month intervention
(1) In-person intervention: 11 face-to-face
counseling sessions (four times weekly,
four times biweekly, three times
monthly). Calorie reduction to 1,200-
2,000 kcal/day (500 kcal/day deﬁcit),
, 25% calories from total fat,
predominantly plant-based diet,
increased ﬁber and reduction in simple
sugars; 150 minutes per week of
moderate-intensity physical activity
(2) Telephone intervention: as for (1) but all
counseling sessions were conducted
over the telephone
(3) Usual care: participants were provided
with nutrition and physical activity
brochures and referred to Yale Cancer
Center Survivorship Clinic, which offers
a two-session weight management
program.
Change from baseline to 6 months:
(1) 25.6 kg (27.1 to 24.1)
(2) 24.8 kg (26.5 to 23.1)
(3) 21.7 kg (23.2 to 20.3)
1 v 3*; 2 v 3*; 1 v 2 (ns)
Change from baseline to 12 months self-
report weight change:
(1) 25.6 kg (28.0 to 23.3)
(2) 26.3 kg (29.9 to 22.6)
(3) 23.8 kg (25.6 to 21.9)
1 v 3; 2 v 3; 1 v 2 (ns)
Retention rate 5 85% (end of
intervention)
Endometrial cancer survivors
SUCCEED40
2014
United States
Risk of bias: 7/10
(moderate)
75 women (menopausal status NR)
Stage I or II endometrial cancer;
postsurgery
Mean 20.7 months since diagnosis
Mean BMI, 36.5 kg/m2
Mean age, 58.4 years
Ethnicity: 91% white
Recruited through Case Comprehensive
Cancer Center tumor registry
12-month intervention
(1) Intervention: 16 60-minute group face-
to-face sessions (10 weekly, six
biweekly); individual face-to-face
counseling visits with physician at 3, 6,
and 12 months; additional support
provided by newsletters, telephone, and
e-mail for 6 months. 5% weight loss
goal; improving diet quality; PA goals
started at 150 minutes per week
increasing to 300 minutes per week by
months 5-6. Focus on lifelong changes
rather than calorie restriction.
(2) Usual care: participants received
informational brochure; physician visits
at baseline, 3, 6, and 12 months but no
lifestyle coaching at these visits
Change from baseline to 12 months:
(1) 23.0% (SD NR)
(2) 11.4% (SD NR)
1 v 2*
Retention rate 5 79.7%
Signiﬁcant between-group difference in
QoL physical well-being domain at
6 months only (P 5 .048). Signiﬁcant
within-group improvement in total
FACT-G scores at 3 months (17.3;
P5 .008) and 6months (16.8; P, .001)
Haggerty41
2016
United States
Risk of bias: 5/10
(moderate)
20 women (menopausal status NR)
Stage I-IV endometrial cancer
Mean time postdiagnosis NR
Mean BMI, 35.4 kg/m2
Mean age, 59.4 years
Ethnicity: 54% white
Recruited through gynecologic oncology
outpatient clinic
6-month intervention
(1) Telemedicine arm: weekly telephone
counseling for 16 weeks then biweekly for
2months. Participants providedwith aWiFi
scale–weekly weights on internet platform
for both participants and staff. Caloric
restriction (on the basis of weight between
1,200-1,800 kcal/day); 30 minutes per day
moderate exercise (eg, walking).
(2) Texting arm: participants received
three to ﬁve personalized text
messages daily from Text4Diet on
various monthly themes—some
informational, some requiring
participant response. Diet and PA goals
same as group (1).
Change from baseline to 6 months (only
reported for n 5 28 who lost weight):
(1) 27.6% (median; range NR)
(2) 24.1% (median; range NR)
1 v 2*
NOTE. Weight outcomes are reported as per original publication and are reported as mean 6 standard deviation, mean (SE) or mean (95% CI).
Abbreviations: BMI, bodymass index; DAMES, Daughters andMothers Against Breast Cancer; ENERGY, Exercise and Nutrition to Enhance Recovery and Good Health
to You; EP, exercise physiologist; ER, estrogen receptor; FACT-G, Functional Assessment of Cancer Therapy General; HER2, human epidermal growth factor receptor 2;
LEAN, Lifestyle, Exercise, and Nutrition; LISA, Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer; NR, not reported; ns, not signiﬁcant; PA,
physical activity; PR, progesterone receptor; QoL, quality of life; SD, standard deviation; STONE, Survivors Taking on Nutrition and Exercise; SUCCEED, Survivors of
Uterine Cancer Empowered by Exercise and Healthy Diet.
*P , .05 for between-group difference.ss
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Ongoing Randomized Trials
A search of two clinical trials registries identiﬁed 22 active
trials in breast cancer survivors, four active trials in endometrial
cancer survivors (one completed in June 2016), and one active trial
in ovarian cancer survivors. Of the 22 current breast cancer trials,
six were single-arm feasibility and efﬁcacy trials, 13 were ran-
domized trials with weight or intermediate outcomes (eg, bio-
markers) as primary outcomes, and three were randomized trials
with cancer end points as primary outcomes. These three trials,
along with the ongoing Diet and Androgens (DIANA)-5 and
Simultaneous Study of Docetaxel-Gemcitabine Combination ad-
juvant treatment, as well as Extended Bisphosphonate and Sur-
veillance (SUCCESS C) trials identiﬁed in the previous review,8 are
summarized in Table 2.45-52 One of the endometrial cancer trials
and the ovarian cancer trial are also examining cancer end points
(Table 2). Of the remaining endometrial cancer trials, one is
a single-arm trial, and two are randomized trials with weight, body
composition, and biomarker primary outcomes.
Breast cancer. DIANA-5. The DIANA-5 study is evaluating
the inﬂuence of a 5-year lifestyle intervention on breast cancer
events.45 In total, 1,208 pre- and postmenopausal women with
early-stage breast cancer at high risk for recurrence (ER-negative,
metabolic syndrome, high testosterone, or high insulin) were
recruited approximately 1.8 years postdiagnosis (between 2008
and 2010). On the basis of Mediterranean and macrobiotic diet
principles, the intervention promotes increasing moderate
physical activity, delivered via group face-to-face sessions in-
cluding cooking classes. The primary outcome is breast cancer
recurrence. Preliminary results on weight change (n = 778) at one
year (22.4 kg v21.0 kg) suggest a relatively small between-group
difference.46 It is unclear when the outcomes from the full trial
will be available.
SUCCESS C. The SUCCESS C trial, with a 2 3 2 factorial
design, is addressing research questions regarding taxane che-
motherapy and the inﬂuence of a lifestyle intervention on
prognosis of early-stage breast cancer.47 More than 2,000 pre-
and postmenopausal women with HER2-negative, node-positive,
or high-risk node-negative disease (BMI, 24 to 40 kg/m2) are
potentially eligible to be randomly assigned to a 2-year life-
style intervention or control condition after chemotherapy. The
intervention is delivered via telephone (up to 20 calls), with
a focus on reducing energy (500 to 1,000 kcal/day deﬁcit) and
fat intake (20% to 25% of energy) and increasing moderate
physical activity (150 to 200 minutes per week). The primary
outcome is disease-free survival, with trial completion expected
in late 2016.
Breast Activity and Healthy Eating After Diagnosis 3
trial. The Breast Activity and Healthy Eating After Diagnosis 3
(B-AHEAD3) trial48 is aiming to recruit 134 pre- and post-
menopausal women diagnosed with advanced breast cancer un-
dergoing chemotherapy. Eligible participants have a prognosis
. 3 months and BMI $ 24 kg/m2. Participants are randomly
assigned to a resistance exercise program or resistance exercise plus
intermittent fasting diet (5:2 diet). The primary trial outcome is
progression-free survival, with chemotherapy toxicity, quality of
life, fatigue, and body composition as secondary outcomes. Re-
cruitment was extended by 12 months, with trial completion
expected by early 2018.
Prevention of Breast Cancer Recurrence Through Weight
Control, Diet, and Physical Activity Intervention trial. The
Prevention of Breast Cancer Recurrence Through Weight Control,
Diet, and Physical Activity Intervention (PREDICOP) trial49 aims
to evaluate a 12-month lifestyle intervention versus usual care on
breast cancer recurrence over 5-year follow-up. The trial aims to
recruit 2,108 pre- and postmenopausal Spanish women diagnosed
with stage I to IIIa breast cancer (BMI, 18 to 40 kg/m2). The
intervention is delivered face to face, with once-weekly nutrition
classes and supervised exercise sessions, with reduced frequency in
the second 6months. Recruitment status of the trial is unclear, with
the registry indicating that the trial is due for completion in 2022.
Breast CancerWeight Loss study. The Breast CancerWeight
Loss (BWEL) study50 will enroll almost 3,200 pre- and post-
menopausal women with stage II or III HER2-negative breast
cancer (BMI$ 27 kg/m2) from clinical centers and practices in the
United States and Canada to determine whether weight loss will
improve breast cancer outcome. Participants will be randomly
assigned to a 2-year weight loss intervention or control condition.
The intervention will be centralized and telephone based, designed
to increase exercise and reduce calories, with the inclusion of
a variety of Fitbit devices and programs (including individual
ﬁtness trackers and a Fitbit smart scale that links to a mobile
dashboard allowing individuals to monitor their progress). Re-
cruitment is scheduled to begin in the second half of 2016. The
primary outcome is invasive disease–free survival, with follow-up
over 10 years.
Endometrial cancer. Mirena 6 Metformin Trial for Endo-
metrial Cancer. The Mirena 6 Metformin Trial for Endometrial
Cancer51 (feMMe) is recruiting 165 women (BMI $ 30 kg/m2)
diagnosed with grade 1 endometrial cancer or complex endo-
metrial hyperplasia with atypia (precancerous). This trial is
evaluating nonsurgical interventions in women who want to retain
fertility or those with a high risk of complications. The trial will
compare an intrauterine device (IUD) alone, IUD plus metformin,
and IUD plus weight loss on the primary outcome of pathologic
complete response at 6-month follow-up. Participants in the
weight loss arm will be provided with a comprehensive sub-
scription to Weight Watchers, including attendance at group
sessions and online tools. The trial is due for completion in June
2018.
Ovarian cancer. Lifestyle Intervention for Ovarian Cancer
Enhanced Survival trial. The Lifestyle Intervention for Ovarian
Cancer Enhanced Survival (LIvES) trial will recruit 1,070 women
(BMI $ 20 kg/m2) diagnosed with epithelial ovarian cancer or
fallopian tube or primary peritoneal carcinoma (stage II to IV at
diagnosis but with no evidence of persistent or recurrent disease)
after completion of chemotherapy.52 Participants are randomly
assigned to receive a 2-year lifestyle intervention (primarily de-
livered via telephone) or usual care, with the primary outcome of
progression-free survival. Completion of the trial is expected by the
end of 2020.
DISCUSSION
Weight control and lifestyle (diet and physical activity) changes
are recommended as an important part of survivorship care,
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Table 2. Ongoing Randomized Controlled Trials Evaluating Weight Loss Interventions in Female Cancer Survivors on Cancer End Points
Study Sample Characteristics Study Arms Outcome
Breast cancer
DIANA-545,46
Italy
1,208 pre- and postmenopausal women
between 2008 and 2010
Stage I-III breast cancer; ER-negative
tumor or high testosterone or insulin
levels or metabolic syndrome
Within 5 years of diagnosis (mean,
approximately 1.8 years postdiagnosis)
BMI eligibility: none (mean, 26.8 kg/m2)
Age eligibility: 35-70 years (mean,
52 years)
Recruited from nine Italian centers
Recruitment completed
(1) Intervention: 5-year Mediterranean-
macrobiotic intervention; group, face-to-
face sessions on tapered schedule (30
in total) plus monthly exercise classes in
year 1. 210 minutes per week of
moderate PA; decrease sedentary;
moderate calorie restriction; reduce
energy density and GI; reduce animal
protein (except ﬁsh)
(2) Control: brochure with
recommendations; two to three
meetings annually
Primary outcome:
Breast cancer recurrence
Estimated completion: NR
SUCCESS C47
Germany
2,292 pre- and postmenopausal women
Node-positive, high-risk node–negative,
HER2-negative breast cancer
Within 6 weeks postsurgery
BMI eligibility: 24-40 kg/m2
Age eligibility: 18 years or older
Recruited via multiple cancer centers
Recruitment completed
2 3 2 factorial design
First randomization: chemotherapy
regimen
Second randomization:
(1) Intervention: 2-year individualized,
telephone-delivered intervention (20 in
total). Calorie deﬁcit 500-1,000 kcal/day;
20%-25% energy from fat; increased
fruit and vegetables; 150-200 minutes
per week of moderate PA
(2) Control: mailed information
Primary outcome:
Disease-free survival
Estimated completion: late 2016
B-AHEAD348
United Kingdom
134 pre- and postmenopausal women
Advanced breast cancer—locally
advanced (no curative surgery) or
distant metastases
Predicted life expectancy $ 3 months
BMI eligibility: $ 24 kg/m2
Age eligibility: 18 years or older
Currently recruiting (extended by
12 months)
(1) Diet and exercise intervention: one
session with dietician and one session
with physiotherapist/EP. 5:2 calorie-
restricted diet; resistance exercises
three times per week
(2) Exercise intervention: one sessionwith
physiotherapist/EP. Resistance
exercises three times per week.
Both groups receive phone calls from
research team every 3 weeks to check
progress and provide support. Research
nurse at treatment center will review at
each chemotherapy treatment.
Primary outcome:
Progression-free survival
Estimated completion: April 2018
PREDICOP49
Spain
2,108 pre- and postmenopausal women
Stage I-IIIa breast cancer
Within 3 months of completing primary
treatment (not including hormonal
treatment) and 15 months since
diagnosis
BMI eligibility: 18-40 kg/m2
Age eligibility: 18-75 years
Unclear on recruitment status
(3) Intervention: 1 year, face-to-face
lifestyle program; one nutrition class and
two supervised exercise sessions per
week for 6 months; monthly sessions
for remaining 6 months. Calorie
reduction while maintaining nutritional
quality; moderate- to high-intensity
exercise.
(4) Usual care: standard
recommendations for weight control;
diet and exercise
Primary outcome:
Breast cancer recurrence
5-year follow-up
Secondary outcomes:
Overall survival
Disease-free survival
Quality of life, fatigue, anxiety, and
depression
Estimated completion: January 2022
BWEL50
United States
3,136 pre- and postmenopausal women
Stage II-III breast cancer; HER2-negative;
Within 12 months from diagnosis; at least
21 days since completion of surgery,
neoadjuvant or adjuvant chemotherapy
BMI eligibility: $ 27 kg/m2
Age eligibility: 18 years or older
Recruitment not yet commenced
(1) Weight loss intervention: 2-year,
individualized, telephone-delivered
weight loss intervention. Tailored
weight loss, calorie restriction, and
physical activity goals.
(2) Control: health education program
Primary outcome:
Invasive disease–free survival
10-year follow-up
Secondary outcomes:
Overall survival
Distant disease–free survival
Estimated completion: May 2030
Endometrial cancer
feMMe51
Australia
165 women diagnosed with grade 1
endometrial cancer or complex
endometrial hyperplasia with atypia.
No extrauterine disease or lymph vascular
invasion
Unsuitable for surgical
treatment—wishing to retain fertility or
high-risk surgical complications
BMI eligibility: . 30 kg/m2
Age eligibility: 18 years or older
Currently recruiting
Randomized 3:5:3
(1) LNG-IUD plus weight loss intervention:
comprehensive subscription to Weight
Watchers. Encouraged to attend group
face-to-face sessions and online tools.
Telephoned every month by research
staff to assess attendance and weight
loss progress.
(2) LNG-IUD plus metformin (500 mg
twice daily)
(3) LNG-IUD alone
Primary outcome:
Pathologic complete response at
6 months (dilation and curette)
Safety screen at 3 months to assess for
progression
Estimated completion: June 2017
(continued on following page)
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particularly for breast cancer survivors.53 This is despite de-
ﬁnitive clinical trial evidence on the impact of weight control on
cancer outcomes. As noted by Goodwin,54 this evidence is im-
portant for patients and clinicians to place value on such rec-
ommendations but also for health funders to pay for such programs.
This review identiﬁed a growing number of ongoing and planned
deﬁnitive trials in breast and ovarian cancer aiming to address this
evidence gap.
The biggest challenge for these trials is how to maintain
participants’ motivation and engagement once intervention con-
tact ceases, to maximize weight loss maintenance. Both the LISA
and ENERGY trials have shown that even with intervention contact
over a 2-year period, small weight regain began after 12 months.
This pattern of weight regain is not unique to cancer survivors and
has been observed in noncancer groups.55 Lessons can also be
learned from primary prevention (Women’s Health Initiative
Dietary Modiﬁcation trial)56,57 and secondary prevention (Women’s
Intervention Nutrition Study)5,58 dietary intervention trials in breast
cancer, where, after long-term dietary interventions of 5.6 and 8.3
years, respectively,5,56 suggested dietary intervention effects on breast
cancer outcomes rapidly attenuated in the postintervention follow-
up when nutritionist contact ended, despite the long duration of the
dietary intervention.
BWEL, LIvES, and SUCCESS C trials are implementing 2-year
interventions, whereas the PREDICOP trial intervention is for only
1 year. The DIANA-5 trial included a 5-year intervention; however,
preliminary data after 1 year46 suggest that weight loss from this
intervention may not be adequate to alter obesity-associated
physiology and tumor microenvironment.54 There is the oppor-
tunity with the BWEL trial, which is yet to commence recruitment,
to learn from the broader weight loss maintenance literature and
identify additional strategies and likely extend intervention con-
tact, to optimize weight loss maintenance and potential beneﬁts on
breast cancer outcomes.
The studies identiﬁed in the current and the prior review8
provide support for the feasibility, safety, and efﬁcacy in achieving
weight loss in breast and endometrial cancer survivors. However,
these and ongoing trials have largely assumed a one-size-ﬁts-all
approach in terms of intervention delivery, targets, and content,
which is unlikely to be appropriate or most effective. In the
ENERGY trial, for example, signiﬁcant differences in intervention
effectiveness were seen depending on participants’ age. A more
personalized approach to weight loss and lifestyle interventions
may be needed. Further research in this area is warranted and can
be informed by evidence in noncancer populations. Post hoc
analysis of ongoing trials to explore outcomes by subgroups (eg,
breast cancer subtype, ethnic group) would also be informative.
In this competitive research funding environment, future
research in this ﬁeld needs to be strategic. Additional single-arm
trials assessing feasibility or short-term randomized trials assessing
efﬁcacy are not necessary. As the effectiveness of centralized in-
terventions by telephone are established59 and evidence on
technology-driven strategies (internet, smart phones, and wear-
ables) continues to mount, such interventions are scalable and
provide an opportunity for implementation in full-scale trials with
cancer outcome end points using pragmatic clinical trial study
designs including cost-effectiveness analyses.
In conclusion, after a decade of preliminary studies, ran-
domized controlled clinical trials are now underway that will
potentially provide deﬁnitive assessment on whether weight loss
can improve clinical outcome in female cancer survivors. However,
ﬁndings from these trials are still a number of years away. Evidence
to support the translation of effective weight loss intervention
programs into wider-scale implementation is needed so that they
can be offered as part of routine survivorship care.
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Table 2. Ongoing Randomized Controlled Trials Evaluating Weight Loss Interventions in Female Cancer Survivors on Cancer End Points (continued)
Study Sample Characteristics Study Arms Outcome
Ovarian cancer
LIvES52
United States
1,070 women diagnosed with epithelial
ovarian cancer, fallopian tube or primary
peritoneal carcinoma, stage II-IV at
diagnosis; no evidence of persistent or
recurrent disease
Within 6-26 weeks of completing
chemotherapy and biologic therapy
BMI eligibility: $ 20 kg/m2
Age eligibility: 18 years or older
Currently recruiting
(1) Lifestyle intervention: 2-year, face-to-
face and telephone-delivered
intervention; initial face-to-face session
and educational materials; tapered
schedule of telephone calls—twice
weekly, once weekly, to biweekly over
6 months, monthly for 6 months,
bimonthly for 12 months. Promote
weight control, increased plasma
carotenoids, adequate micronutrient
intake, monitor fat intake, moderately
low aerobic activity, monitor steps.
(2) Usual care: provided with study
information; tapered calls but on
a reduced frequency (22 calls over
24 months)
Primary outcome:
Progression-free survival
Up to 9 years follow-up
Secondary outcomes:
Quality of life
Change in irritable bowel
syndrome–speciﬁc symptoms
Estimated completion: December 2020
Abbreviations: B-AHEAD, Breast Activity and Healthy Eating After Diagnosis; BWEL, Breast Cancer Weight Loss; DIANA, Diet and Androgens; EP, exercise phys-
iologist; ER, estrogen receptor; feMMe, Mirena 6 metformin in Endometrial Cancer; GI, glycemic index; HER2, human epidermal growth factor receptor 2; LNG-IUD,
levonorgestrel intrauterine device (52 mg releasing at a rate of 25mg per 24 hours); LIvES, Lifestyle Intervention for Ovarian Cancer Enhanced Survival; NR, not reported;
PA, physical activity; PREDICOP, Prevention of Breast Cancer Recurrence Through Weight Control, Diet, and Physical Activity Intervention; SUCCESS C, Simultaneous
Study of Docetaxel-Gemcitabine Combination Adjuvant Treatment, as well as Extended Bisphosphonate and Surveillance Trial.
4246 © 2016 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Chlebowski and Reeves
Downloaded from ascopubs.org by University of Queensland on January 22, 2017 from 130.102.082.101
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
AUTHOR CONTRIBUTIONS
Conception and design: Rowan T. Chlebowski
Financial support: Rowan T. Chlebowski
Administrative support: Rowan T. Chlebowski
Provision of study materials or patients: Rowan T. Chlebowski
Collection and assembly of data: All authors
Data analysis and interpretation: All authors
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors
REFERENCES
1. Chan DS, Vieira AR, Aune D, et al: Body mass
index and survival in women with breast cancer:
Systematic literature review and meta-analysis of 82
follow-up studies. Ann Oncol 25:1901-1914, 2014
2. Protani M, Coory M, Martin JH: Effect of
obesity on survival of women with breast cancer:
Systematic review and meta-analysis. Breast Cancer
Res Treat 123:627-635, 2010
3. Abe R, Kumagai N, Kimura M, et al: Biological
characteristics of breast cancer in obesity. Tohoku J
Exp Med 120:351-359, 1976
4. Chlebowski RT, Aiello E, McTiernan A:Weight
loss in breast cancer patient management. J Clin
Oncol 20:1128-1143, 2002
5. Chlebowski RT, Blackburn GL, Thomson CA,
et al: Dietary fat reduction and breast cancer out-
come: Interim efﬁcacy results from the Women’s
Intervention Nutrition Study. J Natl Cancer Inst 98:
1767-1776, 2006
6. Ballard-Barbash R, Hunsberger S, Alciati MH,
et al: Physical activity, weight control, and breast
cancer risk and survival: Clinical trial rationale and
design considerations. J Natl Cancer Inst 101:
630-643, 2009
7. Ligibel JA, Alfano CM, Hershman D, et al:
Recommendations for obesity clinical trials in cancer
survivors: American Society of Clinical Oncology
statement. J Clin Oncol 33:3961-3967, 2015
8. Reeves MM, Terranova CO, Eakin EG, et al:
Weight loss intervention trials in women with breast
cancer: A systematic review. Obes Rev 15:749-768,
2014
9. de Waard F, Ramlau R, Mulders Y, et al: A
feasibility study on weight reduction in obese post-
menopausal breast cancer patients. Eur J Cancer
Prev 2:233-238, 1993
10. Djuric Z, DiLaura NM, Jenkins I, et al: Com-
bining weight-loss counseling with the weight
watchers plan for obese breast cancer survivors.
Obes Res 10:657-665, 2002
11. Djuric Z, Mirasolo J, Kimbrough L, et al: A pilot
trial of spirituality counseling for weight loss main-
tenance in African American breast cancer survivors.
J Natl Med Assoc 101:552-564, 2009
12. Greenlee HA, Crew KD, Mata JM, et al: A pilot
randomized controlled trial of a commercial diet and
exercise weight loss program in minority breast
cancer survivors. Obesity (Silver Spring) 21:65-76,
2013
13. Harris MN, Swift DL, Myers VH, et al: Cancer
survival through lifestyle change (CASTLE): A pilot
study of weight loss. Int J Behav Med 20:403-412,
2013
14. Mefferd K, Nichols JF, Pakiz B, et al: A cog-
nitive behavioral therapy intervention to promote
weight loss improves body composition and blood
lipid proﬁles among overweight breast cancer sur-
vivors. Breast Cancer Res Treat 104:145-152, 2007
15. Scott E, Daley AJ, Doll H, et al: Effects of an
exercise and hypocaloric healthy eating program on
biomarkers associated with long-term prognosis
after early-stage breast cancer: A randomized
controlled trial. Cancer Causes Control 24:181-191,
2013
16. Shaw C, Mortimer P, Judd PA: A randomized
controlled trial of weight reduction as a treatment for
breast cancer–related lymphedema. Cancer 110:
1868-1874, 2007
17. Shaw C, Mortimer P, Judd PA: Randomized
controlled trial comparing a low-fat diet with aweight-
reduction diet in breast cancer–related lymphedema.
Cancer 109:1949-1956, 2007
18. Thomson CA, Stopeck AT, Bea JW, et al:
Changes in body weight and metabolic indexes in
overweight breast cancer survivors enrolled in
a randomized trial of low-fat vs. reduced carbohydrate
diets. Nutr Cancer 62:1142-1152, 2010
19. Jen KL, Djuric Z, DiLaura NM, et al: Im-
provement of metabolism among obese breast
cancer survivors in differing weight loss regimens.
Obes Res 12:306-312, 2004
20. Sinicrope FA, Dannenberg AJ: Obesity and
breast cancer prognosis: Weight of the evidence.
J Clin Oncol 29:4-7, 2011
21. Iyengar NM, Hudis CA, Dannenberg AJ:
Obesity and cancer: Local and systemic mecha-
nisms. Annu Rev Med 66:297-309, 2015
22. Cheng L, Swartz MD, Zhao H, et al: Hazard of
recurrence among women after primary breast
cancer treatment–a 10-year follow-up using data
from SEER-Medicare. Cancer Epidemiol Biomarkers
Prev 21:800-809, 2012
23. Cossetti RJ, Tyldesley SK, Speers CH, et al:
Comparison of breast cancer recurrence and out-
come patterns between patients treated from 1986
to 1992 and from 2004 to 2008. J Clin Oncol 33:
65-73, 2015
24. Anderson AS, Key TJ, Norat T, et al: European
code against cancer 4th edition: Obesity, body fat-
ness and cancer. Cancer Epidemiol 39:S34-45, 2015
(suppl 1)
25. Arnold M, Pandeya N, Byrnes G, et al: Global
burden of cancer attributable to high body-mass in-
dex in 2012: A population-based study. Lancet Oncol
16:36-46, 2015
26. Dixon SC, Nagle CM, Thrift AP, et al: Adult
body mass index and risk of ovarian cancer by sub-
type: A Mendelian randomization study. Int J Epi-
demiol 45:884-895, 2016
27. Arem H, Chlebowski R, Stefanick ML, et al:
Body mass index, physical activity, and survival after
endometrial cancer diagnosis: Results from the
Women’s Health Initiative. Gynecol Oncol 128:
181-186, 2013
28. Arem H, Irwin ML: Obesity and endometrial
cancer survival: A systematic review. Int J Obes 37:
634-639, 2013
29. Nagle CM, Dixon SC, Jensen A, et al: Obesity
and survival among women with ovarian cancer:
Results from the Ovarian Cancer Association Con-
sortium. Br J Cancer 113:817-826, 2015
30. Protani MM, Nagle CM, Webb PM: Obesity
and ovarian cancer survival: A systematic review and
meta-analysis. Cancer Prev Res (Phila) 5:901-910,
2012
31. Moher D, Liberati A, Tetzlaff J, et al: Preferred
reporting items for systematic reviews and meta-
analyses: The PRISMA statement. BMJ 339:
b2535, 2009
32. Demark-Wahnefried W, Jones LW, Snyder
DC, et al: Daughters and Mothers Against Breast
Cancer (DAMES): Main outcomes of a randomized
controlled trial of weight loss in overweight mothers
with breast cancer and their overweight daughters.
Cancer 120:2522-2534, 2014
33. Goodwin PJ, Segal RJ, Vallis M, et al: Ran-
domized trial of a telephone-based weight loss in-
tervention in postmenopausal women with breast
cancer receiving letrozole: The LISA trial. J Clin Oncol
32:2231-2239, 2014
34. Rock CL, Flatt SW, Byers TE, et al: Results of
the Exercise and Nutrition to Enhance Recovery and
Good Health for You (ENERGY) Trial: A behavioral
weight loss intervention in overweight or obese
breast cancer survivors. J Clin Oncol 33:3169-3176,
2015
35. Demark-Wahnefried W, Colditz GA, Rock CL,
et al: Quality of life outcomes from the Exercise and
Nutrition Enhance Recovery and Good Health for You
(ENERGY)-randomizedweight loss trial among breast
cancer survivors. Breast Cancer Res Treat 154:
329-337, 2015
36. Sedjo RL, Flatt SW, Byers T, et al: Impact of
a behavioral weight loss intervention on comorbid-
ities in overweight and obese breast cancer survi-
vors. Support Care Cancer 24:3285-3293, 2016
37. Sheppard VB, Hicks J, Makambi K, et al: The
feasibility and acceptability of a diet and exercise trial
in overweight and obese black breast cancer survi-
vors: The Stepping STONE study. Contemp Clin
Trials 46:106-113, 2016
38. Swisher AK, Abraham J, Bonner D, et al:
Exercise and dietary advice intervention for sur-
vivors of triple-negative breast cancer: Effects on
body fat, physical function, quality of life, and
adipokine proﬁle. Support Care Cancer 23:2995-3003,
2015
39. Harrigan M, Cartmel B, Loftﬁeld E, et al:
Randomized trial comparing telephone versus in-
person weight loss counseling on body composi-
tion and circulating biomarkers in women treated for
breast cancer: The Lifestyle, Exercise, and Nutrition
(LEAN) study. J Clin Oncol 34:669-676, 2016
40. McCarroll ML, Armbruster S, Frasure HE, et al:
Self-efﬁcacy, quality of life, and weight loss in
overweight/obese endometrial cancer survivors
(SUCCEED): A randomized controlled trial. Gynecol
Oncol 132:397-402, 2014
41. Haggerty AF, Huepenbecker S, Sarwer DB,
et al: The use of novel technology-based weight loss
interventions for obese women with endometrial
hyperplasia and cancer. Gynecol Oncol 140:239-244,
2016
42. Stolley MR, Sharp LK, Oh A, et al: A weight
loss intervention for African American breast cancer
survivors, 2006. Prev Chronic Dis 6:A22, 2009
www.jco.org © 2016 by American Society of Clinical Oncology 4247
Weight Loss and Randomized Trials in Breast Cancer
Downloaded from ascopubs.org by University of Queensland on January 22, 2017 from 130.102.082.101
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
43. Rock CL, Byers TE, Colditz GA, et al: Reducing
breast cancer recurrence with weight loss, a van-
guard trial: The Exercise and Nutrition to Enhance
Recovery and Good Health for You (ENERGY) Trial.
Contemp Clin Trials 34:282-295, 2013
44. von Gruenigen V, Frasure H, Kavanagh MB,
et al: Survivors of uterine cancer empowered by
exercise and healthy diet (SUCCEED): A randomized
controlled trial. Gynecol Oncol 125:699-704, 2012
45. Villarini A, Pasanisi P, Traina A, et al: Lifestyle
and breast cancer recurrences: The DIANA-5 trial.
Tumori 98:1-18, 2012
46. Pasanisi P, Villarini A, Gargano G, et al: A
randomized controlled trial of diet, physical activity
and breast cancer recurrences: The Diana-5 study.
Eur J Cancer 48:S283-S284, 2012 (suppl 5)
47. Rack B, Andergassen U, Neugebauer J, et al:
The German SUCCESS C study: The ﬁrst European
lifestyle study on breast cancer. Breast Care (Basel)
5:395-400, 2010
48. International Standard Randomized Con-
trolled Trial Number Registry: A randomised phase II trial
of intermittent energy restriction and resistance exercise
in women receiving chemotherapy for advanced breast
cancer. http://www.isrctn.com/ISRCTN12841416
49. ClinicalTrials.gov: Prevention of breast cancer
recurrence through weight control, diet, and physical
activity intervention (PREDICOP). https://clinicaltrials.
gov/show/NCT02035631
50. ClinicalTrials.gov: Randomized phase III trial evalu-
ating the role of weight loss in adjuvant treatment of
overweight and obese women with early breast cancer
(BWEL study). https://clinicaltrials.gov/show/NCT02750826
51. Hawkes AL, Quinn M, Gebski V, et al: Im-
proving treatment for obese women with early stage
cancer of the uterus: Rationale and design of the
levonorgestrel intrauterine device 6 metformin 6
weight loss in endometrial cancer (feMME) trial.
Contemp Clin Trials 39:14-21, 2014
52. ClinicalTrials.gov: Can diet and physical ac-
tivity modulate ovarian, fallopian tube and primary
peritoneal cancer progression-free survival? https://
clinicaltrials.gov/show/NCT00719303
53. Runowicz CD, Leach CR, Henry NL, et al:
American Cancer Society/American Society of Clini-
cal Oncology breast cancer survivorship care guide-
line. J Clin Oncol 34:611-635, 2016
54. Goodwin PJ: Obesity and breast cancer out-
comes: How much evidence is needed to change
practice? J Clin Oncol 34:646-648, 2016
55. Look AHEAD Research Group: Eight-year
weight losses with an intensive lifestyle in-
tervention: The look AHEAD study. Obesity (Silver
Spring) 22:5-13, 2014
56. Prentice RL, Caan B, Chlebowski RT, et al:
Low-fat dietary pattern and risk of invasive breast
cancer: The Women’s Health Initiative Randomized
Controlled Dietary Modiﬁcation Trial. JAMA 295:
629-642, 2006
57. Thomson CA, Van Horn L, Caan BJ, et al:
Cancer incidence and mortality during the in-
tervention and postintervention periods of the
Women’s Health Initiative dietary modiﬁcation trial.
Cancer Epidemiol Biomarkers Prev 23:2924-2935,
2014
58. Chlebowski RT, Blackburn GL, Hoy MK, et al:
Survival analyses from the Women’s Intervention
Nutrition Study (WINS) evaluating dietary fat re-
duction and breast cancer outcome. J Clin Oncol 26,
2008 (suppl; abstr 522)
59. Reeves MM, Whelan M, Brackenridge C,
et al: Effectiveness of telephone-delivered in-
terventions for achieving weight loss in overweight
and obese adults: A meta-analysis. Obes Facts 641,
2013 (suppl 1)
n n n
4248 © 2016 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Chlebowski and Reeves
Downloaded from ascopubs.org by University of Queensland on January 22, 2017 from 130.102.082.101
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
Weight Loss Randomized Intervention Trials in Female Cancer Survivors
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are
self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more
information about ASCO’s conﬂict of interest policy, please refer to www.asco.org/rwc or jco.ascopubs.org/site/ifc.
Rowan T. Chlebowski
Honoraria: Novartis, Genentech
Consulting or Advisory Role: Novartis, Genentech, Novo Nordisk,
Amgen, Pﬁzer, Genomic Health
Speakers’ Bureau: Novartis, Genentech
Research Funding:National Institutes of Health/National Cancer Institute
Marina M. Reeves
No relationship to disclose
www.jco.org © 2016 by American Society of Clinical Oncology
Weight Loss and Randomized Trials in Breast Cancer
Downloaded from ascopubs.org by University of Queensland on January 22, 2017 from 130.102.082.101
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
Acknowledgment
We thank the Women’s Health Initiative investigators, staff, and trial participants for their work on the Women’s Health Initiative Dietary
Modiﬁcation trial discussed in this review and for their outstanding dedication and commitment. We also thank Zoe Thomson and
Caroline Terranova (PhD candidates) for research assistant support with the literature search.
© 2016 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Chlebowski and Reeves
Downloaded from ascopubs.org by University of Queensland on January 22, 2017 from 130.102.082.101
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
Ta
bl
e
A1
.
M
et
ho
do
lo
gi
ca
lQ
ua
lit
y
S
co
re
an
d
R
is
k
of
B
ia
s
A
ss
es
sm
en
t
in
R
an
do
m
iz
ed
C
lin
ic
al
Tr
ia
ls
of
W
ei
gh
t
Lo
ss
In
te
rv
en
tio
ns
in
W
om
en
W
ith
B
re
as
t
an
d
E
nd
om
et
ria
lC
an
ce
r
S
tu
dy
B
as
el
in
e
R
es
ul
ts
R
ep
or
te
d
S
ep
ar
at
el
y
fo
r
E
ac
h
G
ro
up
on
To
ta
l
C
on
se
nt
ed
S
am
pl
e
R
an
do
m
iz
at
io
n
C
le
ar
ly
D
es
cr
ib
ed
an
d
A
de
qu
at
el
y
D
on
e
D
ro
po
ut
#
20
%
fo
r
#
6-
M
on
th
Fo
llo
w
-U
p
an
d
#
30
%
fo
r
.
6-
M
on
th
Fo
llo
w
-U
p
A
ss
es
so
r
B
lin
di
ng
W
ei
gh
t
O
ut
co
m
es
A
ss
es
se
d
$
6
M
on
th
s
A
ft
er
B
as
el
in
e
In
te
nt
io
n-
to
-
Tr
ea
t
A
na
ly
si
s
an
d
an
A
pp
ro
pr
ia
te
A
pp
ro
ac
h
to
M
is
si
ng
D
at
a
P
ot
en
tia
l
C
on
fo
un
de
rs
A
cc
ou
nt
ed
fo
r
in
A
na
ly
se
s,
In
cl
ud
in
g
B
as
el
in
e
Le
ve
l
of
B
eh
av
io
r
S
um
m
ar
y
R
es
ul
ts
P
re
se
nt
ed
P
lu
s
E
ff
ec
tS
iz
e
P
lu
s
P
re
ci
si
on
E
st
im
at
es
P
ow
er
C
al
cu
la
tio
n
R
ep
or
te
d
an
d
S
tu
dy
A
de
qu
at
el
y
P
ow
er
ed
W
ei
gh
t
O
bj
ec
tiv
el
y
M
ea
su
re
d
S
co
re
/1
0
(ri
sk
of
bi
as
)
B
re
as
t
ca
nc
er
D
A
M
E
S
3
2
X
X
3
?
3
3
3
X
X
3
5/
10
(m
od
er
at
e)
LI
S
A
3
3
3
3
3
?
3
3
3
3
3
3
9/
10
(lo
w
)
E
N
E
R
G
Y
3
4
,4
3
3
X
3
3
3
?
3
X
3
3
7/
10
(m
od
er
at
e)
S
te
pp
in
g
S
TO
N
E
3
7
X
X
X
?
X
X
3
X
X
3
2/
10
(h
ig
h)
S
w
is
he
r
et
al
3
8
X
X
X
?
X
X
?
X
3
3
2/
10
(h
ig
h)
LE
A
N
3
9
3
3
3
3
3
3
X
X
3
3
8/
10
(lo
w
)
E
nd
om
et
ria
lc
an
ce
r
S
U
C
C
E
E
D
4
0
,4
4
3
X
3
?
3
?
3
3
3
3
7/
10
(m
od
er
at
e)
H
ag
ge
rt
y
et
al
4
1
3
X
3
?
3
X
?
X
3
3
5/
10
(m
od
er
at
e)
N
O
TE
.
C
rit
er
ia
sc
or
ed
as
3
pr
es
en
t
(1
po
in
t);
X
ab
se
nt
(0
po
in
ts
);
?
un
cl
ea
r
or
in
ad
eq
ua
te
ly
de
sc
rib
ed
(0
po
in
ts
).
A
bb
re
vi
at
io
ns
:
D
A
M
E
S
,
D
au
gh
te
rs
an
d
M
ot
he
rs
A
ga
in
st
B
re
as
t
C
an
ce
r;
E
N
E
R
G
Y
,
E
xe
rc
is
e
an
d
N
ut
rit
io
n
to
E
nh
an
ce
R
ec
ov
er
y
an
d
G
oo
d
H
ea
lth
to
Y
ou
;
LE
A
N
,
Li
fe
st
yl
e,
E
xe
rc
is
e,
an
d
N
ut
rit
io
n;
LI
S
A
,
Li
fe
st
yl
e
In
te
rv
en
tio
n
S
tu
dy
in
A
dj
uv
an
t
Tr
ea
tm
en
t
of
E
ar
ly
B
re
as
t
C
an
ce
r;
S
TO
N
E
,
S
ur
vi
vo
rs
Ta
ki
ng
on
N
ut
rit
io
n
an
d
E
xe
rc
is
e;
S
U
C
C
E
E
D
,
S
ur
vi
vo
rs
of
U
te
rin
e
C
an
ce
r
E
m
po
w
er
ed
by
E
xe
rc
is
e
an
d
H
ea
lth
y
D
ie
t.
A
pp
en
di
x
www.jco.org © 2016 by American Society of Clinical Oncology
Weight Loss and Randomized Trials in Breast Cancer
Downloaded from ascopubs.org by University of Queensland on January 22, 2017 from 130.102.082.101
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
